[1] Zhang L X,Tu D H,Enarson D A.The impact of directly-ob-served treatment on the epidemiology of tuberculosis in Beijing[J].lnt J Tuberclung Dis,2000,4(10):904~910.
[2] Zhang L X,Kan G Q. Tuberculosis control program in Beijing[J].ubercle Lung Disease,1992,73:162~166.
[3] Zhang L X,Tu D H, He G X,et al. Risk of tuberculosis infection and tuberculous meningitis after discontinuation of bacillus calmette-Guerin in Beijing [J]. Am J Respir Crit Care Med 2000,162:1314~1317.
[4] Bloch A B, Geore M C,Ida M 0, et al. Nationwide survey of drug-resistant tuberculosis in the United States[J].JAM A,1994,271:665-671.
[5] Zhang L X, Kan G Q. Tu D H,et al. Trend of initial resistance of tubercle bacilli isolated from new patients with pulmonary tuberculosis and its correlation with the tuberculosis program in Beijing[J]. Tubercle Lung Disease,1995,76:100~103.
[6] 何国钧.抗结核药物研究进展[J].中国防痨杂志,1996,18(3):136~139.
[7] WHO/IUATLD Global Working Croup on Antituberculosis Drug Resistance Surveilance. Guidelines for surveillance of drug resistance in tuberculosis[M].Geneva:WHO,1996.
[8] John Crofton, Pierre Chaulet,Dermot Maker(肖和平,杨敏译).耐药结核病处理指南[M].上海:卫生部结核病控制分中心,1997,4~41.
[9] 中华结核和呼吸杂志编辑委员会.全国多耐药结核病学术会议纪要[J].中华结核和呼吸杂志,1997,20(6):382~384.
[10] Dermot Maher, Pierre Chaulet, Sergio Spinaci, et al. Treatment of tuberculosis guidelines for national programmes [M]. WHO/T/97.220:26~31.
[11] WHO. Anti-tuberculosis drug resistance in the world [M].WHO/TB/97.229:154~227.
[12] 陈新谦.金有豫,编.新编药物学,第12版[M].北京:人民卫生出版社,1988,130~136.
[13] 法国维德OVP,出版社.维德临床用药年鉴(1999年版)[M].北京:中信出版社,维德出版社,1999.433~435.
[14] Paul Farmer, Jim Yong Kim,Carole D. Mitniclc, Mercedes Becerra. Protocol for the implementation of individualized treatment regimens for multidrug resistant tuberculosis in resource-poor settings [M]. WHO/TB/99.260:1~15.
[15] 中华人民共和国卫生部疾病控制司,卫生部医政司.全国结核病防治工作手册[M].北京,1999,52~61.
[16] 肖和平,何国钧.耐多药结核病诊断与处理的研讨[J].中国防痨杂志,1999,21(S):21~22.
[17] Mukund Uplekar(肖和平,张祖荣,章俊译).结核病临床手册[M].上海:复旦大学出版社,1999.50~73.
[18] John Crofton, Norman Home, Fred Miller(王撷秀,屠德华,安燕生译).临床结核病,第2版[M].北京:科学出版社,2000.160~162.
[19] 肖和平.肺结核诊治进展.见:黄绍光主编.肺内科新进展[M].北京:人民卫生出版社,2000.178~201.
[20] 肖和平,何国钧.耐多药结核病的诊断与化疗探寻[J].结核病与胸部肿瘤,2000,(1):5~10.
[21] Michael D. Iseman. A Clinician's Guide to Tuberculosis:drug-resistant tuberculosis[J]. New York: Lippincott Williams & Wilkins.2000.323~324.
[22] Bleed D,Watt C, Dye C. Global tuberculosis Control [M]. WHO/CDS/TB.275:184.
[23] Rajesh Gupta,Brenner J G,Jim Young Kim.et al. Procurement of second-line anti-tuberculosis drugs for DOTS-plus pilot projects [M].WHO/CDS/TB/2000.276:1~14.
[24] 肖和平,何国钧.结核分支杆菌感染,见:汪复主编.抗感染药物临床应用手册[M].北京:人民卫生出版社,2001.102~106.
[25] 中华人民共和国卫生部.2000年全国结核病流行病学抽样调査报告[R].北京:2002,42~48.
[26] 中华人民共和国卫生部疾病控制司.中国结核病防治规划实施工作指南[M].北京:中华人民共和国卫生部,2002.6~34.
|